Marie Attwood
Overview
Explore the profile of Marie Attwood including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
419
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gadiya Y, Genilloud O, Bilitewski U, Bronstrup M, von Berlin L, Attwood M, et al.
J Chem Inf Model
. 2025 Feb;
65(5):2416-2431.
PMID: 39987507
While the useful armory of antibiotic drugs is continually depleted due to the emergence of drug-resistant pathogens, the development of novel therapeutics has also slowed down. In the era of...
2.
Carson A, Bowker K, Attwood M, Noel A, MacGowan A
JAC Antimicrob Resist
. 2024 Jul;
6(4):dlae108.
PMID: 39005592
No abstract available.
3.
Santerre Henriksen A, Arena F, Attwood M, Canton R, Gatermann S, Naas T, et al.
Microbiol Spectr
. 2024 Jun;
:e0418123.
PMID: 38904361
Importance: This study collected a notably large number of Enterobacterales isolates from Europe, including meropenem- and β-lactam/β-lactamase inhibitor combination-resistant isolates against which the activities of cefiderocol and developmental β-lactam/β-lactamase inhibitor...
4.
Morrissey I, Hawser S, Kothari N, Dunkel N, Quevedo J, Belley A, et al.
J Glob Antimicrob Resist
. 2024 May;
38:71-82.
PMID: 38723712
Objectives: This study was performed to investigate the activity of the novel ß-lactam/ß-lactamase inhibitor combination cefepime/enmetazobactam, against recently circulating Enterobacterales isolates from Europe from 2019 to 2021. Methods: A total...
5.
Attwood M, Griffin P, Noel A, Albur M, MacGowan A
J Antimicrob Chemother
. 2023 Aug;
78(9):2254-2262.
PMID: 37527369
Objectives: To use a pre-clinical pharmacokinetic infection model to assess the antibacterial effect of ceftolozane/tazobactam alone or in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa strains with MICs at...
6.
Muller A, Attwood M, van den Berg S, Chavan R, Periasamy H, Noel A, et al.
J Antimicrob Chemother
. 2022 Oct;
77(12):3504-3509.
PMID: 36253951
Background: Very limited studies, so far, have been conducted to identify the pharmacodynamic targets of cefepime, a well-established fourth-generation cephalosporin. As a result, conventional targets representing the cephalosporin class are...
7.
Pantel L, Guerin F, Serri M, Gravey F, Houard J, Maurent K, et al.
Antimicrob Agents Chemother
. 2022 Oct;
66(11):e0077622.
PMID: 36200761
The Enterobacter cloacae complex (ECC) is a group of diverse environmental and clinically relevant bacterial species associated with a variety of infections in humans. ECC have emerged as one of...
8.
Frost J, Hamilton F, Arnold D, Elvers K, Shah A, Armitage A, et al.
Wellcome Open Res
. 2022 Aug;
7:173.
PMID: 35935705
Marked reductions in serum iron concentrations are commonly induced during the acute phase of infection. This phenomenon, termed hypoferremia of inflammation, leads to inflammatory anemia, but could also have broader...
9.
Noel A, Attwood M, Bowker K, MacGowan A, Albur M
J Antimicrob Chemother
. 2022 Feb;
77(5):1306-1312.
PMID: 35137096
Background: There is surprisingly little comparative published data on the bactericidal action of different sub-classes of β-lactams against aerobic Gram-negative rods, and the assumption is that all behave in the...
10.
MacGowan A, Hamilton F, Bayliss M, Read L, Attwood M, Noel A, et al.
Microb Drug Resist
. 2022 Jan;
28(5):611-612.
PMID: 35099290
No abstract available.